Anakinra, an IL-1 receptor antagonist that inhibits the activity of both IL-1α and IL-1β, is effective in reducing acute gout pain and inflammation and may be a reasonable option in patients with CKD [27–32]. The gene discussed is IL1A; the disease is gout.